BRCA2 and pachyonychia congenita: It has been well established that the BRCA2 mutation addresses worse metastasis-free survival (MFS) and cancer-specific survival (CSS) after primary, radical treatment for localized PC, so whether setting up a pretreatment screening of DNA repair mutations or managing them after the first diagnosis of PC to guide treatment decisions remains a challenge.